Abstract
Background aims
Chimeric antigen receptor (CAR) T-cell therapy is a breakthrough treatment for patients
with relapsed or refractory diffuse large B-cell lymphoma. However, many patients
do not achieve remission or relapse after remission. Previous studies have demonstrated
that eosinophils have synergistic anti-tumor effects with CD8+T cells and pre-CAR T-eosinophil counts are associated with the efficacy of CAR T
cells.
Methods
We retrospectively analyzed the eosinophil counts of patients with diffuse large B-cell
lymphoma and found it changed remarkably pre- and post-CAR T-cell therapy.
Results
Patients who achieved complete remission after CAR T-cell infusion had greater post-CAR
T-eosinophil counts than those who did not. Kaplan–Meier curves showed that patients
with greater eosinophil counts during the second month after CAR T-cell infusion had
superior progression-free survival and overall survival compared with those with lower
eosinophil counts.
Conclusions
For patients who responded to CAR T-cell therapy, eosinophil counts also can be used
to predict 6-month duration of response. In conclusion, the post-CAR T-eosinophil
count is associated with the prognosis of patients treated with CAR T-cell therapy
and can be used to clinically identify patients who can achieve longer remission after
CAR T-cell infusion.
Key Words
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to CytotherapyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium.J Clin Oncol. 2020; 38: 3119-3128
- Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies.Blood Adv. 2020; 4: 4669-4678
- Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma.Blood. 2020; 135: 2106-2109
- Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial.The Lancet Oncology. 2019; : 20
- Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study.Lancet Oncol. 2021; 22: 1403-1415
- Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.N Engl J Med. 2019; 380: 45-56
- Outcomes of patients with aggressive B-Cell lymphoma after failure of anti-CD19 CAR T-Cell Therapy: A DESCAR-T analysis.Blood. 2022;
- Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma.Blood Adv. 2020; 4: 5607-5615
- Day 30 SUVmax Predicts Progression in Lymphoma Patients Achieving PR/SD After CAR T-cell Therapy.Blood Adv. 2022;
- Impact of TP53 Genomic Alterations in Large B-Cell Lymphoma Treated With CD19-Chimeric Antigen Receptor T-Cell Therapy.J Clin Oncol. 2021; Jco2102143
- An eosinophil-dependent mechanism for the antitumor effect of interleukin-4.Science (New York, NY). 1992; 257: 548-551
- Tumor eosinophil infiltration and improved survival of colorectal cancer patients: Iowa Women's Health Study.Mod Pathol. 2016; 29: 516-527
- Eosinophil accumulation predicts response to melanoma treatment with immune checkpoint inhibitors.Oncoimmunology. 2020; 91727116
- Pretreatment Eosinophil Counts in Patients With Advanced or Metastatic Urothelial Carcinoma Treated With Anti-PD-1/PD-L1 Checkpoint Inhibitors.Journal of immunotherapy (Hagerstown, Md: 1997). 2021;
- Leucocyte and eosinophil counts predict progression-free survival in relapsed or refractory classical Hodgkin Lymphoma patients treated with PD1 inhibition.Br J Haematol. 2018; 181: 837-840
- Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8(+) T cells.Nature immunology. 2015; 16: 609-617
- Peripheral eosinophil counts predict efficacy of anti-CD19 CAR-T cell therapy against B-lineage non-Hodgkin lymphoma.Theranostics. 2021; 11: 4699-4709
- Human pluripotent stem cell-derived eosinophils reveal potent cytotoxicity against solid tumors.Stem cell reports. 2021; 16: 1697-1704
- Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma.Haematologica. 2020;
- Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma.Haematologica. 2021; 106: 978-986
- Eosinophils in Cancer: Favourable or Unfavourable?.Current medicinal chemistry. 2016; 23: 650-666
- Clinical impact of tumor-infiltrating inflammatory cells in primary small cell esophageal carcinoma.Int J Mol Sci. 2014; 15: 9718-9734
- Peritumoral eosinophils predict recurrence in colorectal cancer.Mod Pathol. 2015; 28: 403-413
- Tissue eosinophilia correlates strongly with poor prognosis in nodular sclerosing Hodgkin's disease, allowing for known prognostic factors.Blood. 2000; 95: 1207-1213
- Tumor-associated eosinophilic infiltrate of cervical cancer is indicative for a less effective immune response.Human pathology. 1996; 27: 904-911
- The Prognostic Value of the New Combined Hemo-Eosinophil Inflammation Index (HEI Index): A Multicenter Analysis of Anal Cancer Patients Treated with Concurrent Chemo-Radiation.Cancers. 2021; 13
- Clinical lessons learned from the first leg of the CAR T cell journey.Nat Med. 2019; 25: 1341-1355
Article info
Publication history
Published online: November 28, 2022
Accepted:
October 27,
2022
Received:
July 19,
2022
Publication stage
In Press Corrected ProofIdentification
Copyright
© 2022 International Society for Cell & Gene Therapy. Published by Elsevier Inc. All rights reserved.
